RxDoctor Payments Data

Julie Lindstrom, DO

Family Medicine · Broken Bow, NENPI 1528098407

Payments from drug & device makers

$1,184in general payments, 2019–2025

Across 80 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$279
  • Johnson & Johnson$207
  • Pfizer$151
  • Amgen$104
  • AbbVie$85
  • Astellas Pharma US Inc$66
  • plus $292 from 11 others

What the payments were for

  • Food & beverage$1,184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,184 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$223,462
Medicare patients
420
Services billed
5,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$69,858
OzempicSemaglutide34$39,080
JardianceEmpagliflozin56$38,202
XareltoRivaroxaban52$27,726
TrulicityDulaglutide15$15,646
FarxigaDapagliflozin Propanediol29$11,700
JanuviaSitagliptin Phosphate21$11,305
RybelsusSemaglutide12$10,816
Breo ElliptaFluticasone/Vilanterol20$8,008
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$6,004
ArexvyRsvpref3 Antigen/As01e/Pf17$5,289
MyrbetriqMirabegron22$5,075
Potassium Chloride190$4,014
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$3,972
Sucralfate42$3,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$69,858123 claims
Novo NordiskOzempic, Rybelsus$279$49,89646 claims
Boehringer IngelheimJardiance$52$38,20256 claims
Johnson & JohnsonXarelto, Invokana$207$31,03263 claims
Lilly USA, LLCTrulicity$57$15,64615 claims
AstraZenecaFarxiga$16$11,70029 claims
MerckJanuvia$19$11,30521 claims
Astellas Pharma US IncMyrbetriq$66$5,07522 claims
AbbVieSynthroid$85$2,51152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Broken Bow

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →